HHS, Defense to fund antibiotic development for drug-resistant infections

Modern Healthcare: Federal health officials will invest nearly $100 million to develop a new antibiotic that can treat drug-resistant "superbugs" for which there are currently few or no treatment options.

HHS will collaborate with the Defense Department and Malvern, Pa.-based drugmaker VenatoRx Pharmaceuticals on the company's compound VNRX-5133. When combined with the intravenous antibiotic cefepime, the compound might combat bacteria that is resistant to currently available antibiotics, the agencies said Monday.

Read article

i360Gov Newsletters

The most significant government policy, business, and technology news and analysis delivered to your inbox.

Subscribe Now

Trending